Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.

Citation data:

Blood, ISSN: 1528-0020, Vol: 129, Issue: 18, Page: 2526-2536

Publication Year:
Usage 4
Abstract Views 4
Captures 33
Readers 33
Mentions 2
Blog Mentions 1
News Mentions 1
Social Media 6
Tweets 6
Citations 3
Citation Indexes 3
Keina M. C. Dourado; June Baik; Vanessa K. P. Oliveira; Miriam Beltrame; Ami Yamamoto; Charles P. Theuer; Camila A. V. Figueiredo; Michael R. Verneris; Rita C. R. Perlingeiro
American Society of Hematology
Biochemistry, Genetics and Molecular Biology; Immunology and Microbiology; Medicine
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
Endoglin (CD105), a receptor of the transforming growth factor-β superfamily, has been reported to identify functional long-term repopulating hematopoietic stem cells, and has been detected in certain subtypes of acute leukemias. Whether this receptor plays a functional role in leukemogenesis remains unknown. We identified endoglin expression on the majority of blasts from patients with acute myeloid leukemia (AML) and acute B-lymphoblastic leukemia (B-ALL). Using a xenograft model, we find that CD105 blasts are endowed with superior leukemogenic activity compared with the CD105 population. We test the effect of targeting this receptor using the monoclonal antibody TRC105, and find that in AML, TRC105 prevented the engraftment of primary AML blasts and inhibited leukemia progression following disease establishment, but in B-ALL, TRC105 alone was ineffective due to the shedding of soluble CD105. However, in both B-ALL and AML, TRC105 synergized with reduced intensity myeloablation to inhibit leukemogenesis, indicating that TRC105 may represent a novel therapeutic option for B-ALL and AML.